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Abstract: Alzheimer’s disease (AD) is an intractable, neurodegenerative disease that appears to be brought about by both 
genetic and non-genetic factors. The neuropathology associated with AD is complex, although amyloid plaques composed 
of the -amyloid peptide (A) are hallmark neuropathological lesions of AD brain. Indeed, A plays an early and central 
role in this disease. -site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is the initiating enzyme in A 
genesis and BACE1 levels are elevated under a variety of conditions. Given the strong correlation between A and AD, 
and the elevation of BACE1 in this disease, this enzyme is a prime drug target for inhibiting A production in AD. How-
ever, nine years on from the initial identification of BACE1, and despite intense research, a number of key questions re-
garding BACE1 remain unanswered. Indeed, drug discovery and development for AD continues to be challenging. While 
current AD therapies temporarily slow cognitive decline, treatments that address the underlying pathologic mechanisms of 
AD are completely lacking. Here we review the basic biology of BACE1. We pay special attention to recent research that 
has provided some answers to questions such as those involving the identification of novel BACE1 substrates, the poten-
tial causes of BACE1 elevation and the putative function of BACE1 in health and disease. Our increasing understanding 
of BACE1 biology should aid the development of compounds that interfere with BACE1 expression and activity and may 
lead to the generation of novel therapeutics for AD. 
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INTRODUCTION 
Several major pathological abnormalities characterize 
AD, including the A-containing extracellular amyloid 
plaques, intracellular neurofibrillary tangles, neuroinflamma-
tion, neuronal dysfunction and ultimately neuron death. 
Mounting evidence suggests that A plays a critical early 
role in AD pathogenesis. Familial AD (FAD) is caused by 
autosomal dominant mutations in either APP, on chromosome 
21, or the presenilin (PS1, PS2) genes on chromosomes 14 
and 1 respectively. A strong genetic correlation exists be-
tween FAD and the 42 amino acid A form (A42; reviewed 
in [1-3]). APP and PS mutations increase A42 production 
and cause FAD with nearly 100% penetrance. Down’s syn-
drome (DS) patients, who are trisomic for chromosome 21 
and thus have an extra copy of the APP gene, and FAD fami-
lies with a duplicated APP gene locus [4] exhibit total A 
overproduction and all develop early-onset AD. In FAD, the 
A42 increase is present years before AD symptoms arise, 
suggesting that A42 is likely to initiate AD pathophysiology.  
FAD cases account for a small fraction of all AD cases 
and for the remaining ~98% of so-called sporadic or late-
onset AD (LOAD) cases, the underlying cause (s) remain 
elusive, although specific risk factors for this disease are,   
at least in part, understood. Aging is the major risk factor for 
LOAD, though the basis of this association remains 
 
*Address correspondence to this autor at the Department of Cell and Mo-
lecular Biology, Feinberg School of Medicine, Northwestern University, 
303 E. Chicago Avenue, Chicago, IL 60611, USA;  
E-mail: r-vassar@northwestern.edu 
unknown. The apolipoprotein (Apo) E4 allele on chromo-
some 19, is also a strong risk factor for LOAD [5] and is 
associated with atherosclerosis. Interestingly, there is a close 
relationship between AD and cardiovascular disease with 
coronary artery disease, hypertension and hypercholes-
terolemia, amongst others, being significant AD risk factors 
[6-10]. How such risk factors impact AD risk and the puta-
tive molecular mechanisms underlying this association are 
the current focus of intense investigation. However, the ro-
bust association of A42 overproduction with FAD argues 
strongly in favor of a critical role for A42 in the etiology of 
AD, including in LOAD. Consequently, strategies to lower 
A42 levels in the brain are anticipated to be of therapeutic 
benefit in AD.  
A GENERATION 
A peptide generation is mediated by the endoproteolysis 
of APP, a large, ubiquitously expressed, type 1 integral 
membrane protein, via  the pro-amyloidogenic - and -
secretases, and the anti-amyloidogenic, -secretase. BACE1 
is the -secretase that initiates, and is essential for, A gene-
sis by cleaving APP to form the N-terminus of A at the 
Asp+1 residue of the A sequence. This scission liberates 
two cleavage fragments: a secreted APP ectodomain, APPs 
and a membrane-bound carboxyl terminal fragment (CTF), 
C99. -secretase cleaves C99 to generate the C-terminus of 
the A peptide and an APP intracellular domain (AICD). -
secretase is tetrameric a protein complex [11] composed of 
PS1 or PS2 [12, 13], nicastrin [14], Aph1 and Pen2 [15, 16]. 
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majority of A peptides liberated by -secretase activity are 
40 amino acids in length (A40), a small proportion end at 
amino acid 42 (A42). Most FAD mutations affect the -
secretase-dependent cleavage to cause excess generation of 
A42 in FAD. In an alternative, non-amyloidogenic path-
way, APP is cleaved by -secretase, the activity of which 
precludes A formation, as -secretase cleavage occurs 
within the A domain at Leu+17. -secretase cleavage pro-
duces the secreted APPs ectodomain, and a CTF, C83, 
which in turn is cleaved by -secretase to form the non-
amyloidogenic 3kDa fragment, p3 and a second AICD. 
Three different proteases appear to be responsible for the -
secretase activity: TACE (TNF- converting enzyme; [17], 
ADAM (a disintegrin and metalloprotease domain protein)-9 
and ADAM-10 [18]. In many instances, the - and -secre- 
tase moieties compete for APP substrate [19, 20], and an 
increase in one cleavage event is coupled with a reciprocal 
decrease in the other.  
THE IDENTIFICATION OF BACE1 AS THE  
-SECRETASE 
In 1999-2000 several groups identified a novel aspartic 
protease, BACE1 (also known as memapsin 2; and Asp 2) 
[19, 21-24] as the -secretase. BACE1 exhibited all the pre-
viously determined characteristics of -secretase. Earlier, 
maximal  -secretase activity had been observed in neural 
tissue and neuronal cell lines [25], although some activity 
was detected in the majority of body tissues [26]. Interest-
ingly, astrocytes exhibited less -secretase activity than neu-
rons [27]. Indeed, the pattern and level of BACE1 expression 
is largely consistent with those of -secretase activity in cells 
and tissues [19, 23, 28]. The levels of BACE1 mRNA are 
highest in brain and pancreas and are significantly lower in 
most other tissues. Moreover, BACE1 mRNA is highly ex-
pressed in neurons but little is found in resting glial cells of 
the brain, as expected for -secretase. The protein is abun-
dant in both normal human and AD brain [19, 28]. The high 
pancreatic mRNA expression was initially confusing, given 
the low levels of -secretase activity in this tissue [22]. 
However, it was subsequently reported that BACE1 mRNA 
transcripts in pancreas largely consist of a splice variant 
missing the majority of exon 3 [29, 30]. This splice variant 
encodes a BACE1 isoform devoid of -secretase activity, 
thus reconciling the paradoxically high BACE1 mRNA lev-
els with the low -secretase activity found in the pancreas. 
The functional relevance of this pancreas-specific splice 
variant remains unclear. 
When transfected into stable APP-overexpressing cell 
lines, BACE1 induces a dramatic increase in -secretase 
activity. APPs and C99, the immediate products of -
secretase cleavage, are increased several fold over levels 
found in untransfected cells, and A production is also ele-
vated. Interestingly, APPs levels are reduced upon BACE1 
transfection, suggesting that - and -secretases compete for 
APP substrate in cells. Treatment of APP-overexpressing 
cells with BACE1 antisense oligonucleotides decreases 
BACE1 mRNA levels, inhibits -secretase activity [19, 23] 
and reduces production of APPs, C99, and A in cells; 
conversely, APPs and C83 generation is elevated. 
-Secretase activity in cells efficiently cleaves mem-
brane-bound substrates only [31], and has maximal activity 
at acidic pH, [32-34], with the highest activity being detected 
in the acidic subcellular compartments of the secretory 
pathway, including the Golgi apparatus, trans Golgi network 
(TGN), and endosomes [35, 36]. These data suggest that the 
active site of -secretase is located within the lumen of 
acidic intracellular compartments. As predicted, BACE1 is 
resistant to inhibition by pepstatin and has optimal activity at 
~pH 4.5, being localized within acidic subcellular compart-
ments of the secretory pathway, primarily the Golgi appara-
tus, TGN and endosomes. The 501 amino acid sequence of 
BACE1 bears the hallmark features of eukaryotic aspartic 
proteases of the pepsin family. BACE1 has two aspartic pro-
tease active site motifs, DTGS (residues 93-96) and DSGT 
(residues 289-292), and mutation of either aspartic acid ren-
ders the enzyme inactive [21, 37]. Like other aspartic prote-
ases, BACE1 has an N-terminal signal sequence (residues 1-
21) and a pro-peptide domain (residues 22-45) that are re-
moved post-translationally, so the mature enzyme begins at 
residue Glu46 [37]. Importantly, BACE1 has a single trans-
membrane domain near its C-terminus (residues 455-480) 
and a palmitoylated cytoplasmic tail [38]. BACE1 is a type I 
membrane protein with a luminal active site, features pre-
dicted for -secretase. The position of the BACE1 active site 
within the lumen of intracellular compartments provides the 
correct topological orientation for cleavage of APP at the -
secretase site. Similar to other aspartic proteases, BACE1 
has several N-linked glycosylation sites and six luminal cys-
teine residues that form three intramolecular disulfide bonds 
[39]. 
Site-directed mutagenesis of the amino acids surrounding 
the cleavage site in APP defined the sequence preference of 
the -secretase [31], and the complete specificity of this pro-
tease was derived on the basis of substrate kinetics and the 
screening of a combinatorial inhibitor library [40]. Substitu-
tions of larger hydrophobic amino acids (such as Leu found 
in the Swedish FAD mutation) for the Met residue at P1 im-
prove the efficiency of -secretase cleavage. Conversely, 
substitution of the smaller hydrophobic amino acid Val at the 
same position inhibits cleavage. Many other substitutions at 
this site and at surrounding positions decrease cleavage, and 
indicate that the -secretase is highly sequence-specific. In-
terestingly, a number of A species with different N-
terminus residues have been identified. Radiosequencing 
demonstrated that A isolated from amyloid plaques, as well 
as that produced in cell lines, predominantly begins at the 
Asp+1 residue of A [41], although minor A species begin 
at Val-3, Ile-6, and Glu+11 [26]. Inhibitor studies suggest 
that the Val-3 and Ile-6 species are generated by a protease 
that is different from the -secretase [42]. However, the 
Glu+11 species is produced in parallel with Asp+1 A [43], 
suggesting that -secretase is responsible for cleaving at both 
these positions. Interestingly, the Glu+11 species is the pre-
dominant form of A made in rat primary neuron cultures 
[43]. Importantly, BACE1 cleaves APP only at the known -
secretase sites of Asp+1 and Glu+11 of A [19]. Moreover, 
purified recombinant BACE1 directly cleaves APP sub-
strates at these same sites in vitro, demonstrating that the 
BACE1 molecule intrinsically exhibits protease activity [19, 
23]. The sequence specificity of purified BACE1 is the same 
as -secretase. For example, it cleaves Swedish mutant APP 
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cleave a P1 Met-Val mutant substrate that is resistant to -
secretase cleavage.  
Taken as a whole, the properties of BACE1 correlate 
very well with the previously established characteristics of 
-secretase activity in cells and tissues. 
BACE1 AS A THERAPEUTIC TARGET 
BACE1 is considered a prime drug target for lowering 
cerebral A levels in the treatment and/or prevention of AD 
for a number of reasons. Most importantly, BACE1 is the 
initiating and putatively rate-limiting enzyme in A genera-
tion and BACE1 inhibition would block the production of 
A and prevent the development of A-associated patholo-
gies. Furthermore, initial reports indicated that BACE1 
knockout (BACE1
-/-) mice were free of any harsh phenotype 
and showed no pathological abnormalities, although more 
recent analysis does indicate subtle behavioral alterations in 
mice lacking BACE1 expression (discussed below). It has 
been speculated that BACE1 is a more suitable therapeutic 
target than either - or -secretase, although, as described 
later, there are a number of caveats associated with BACE1 
inhibition. Presenilin, the catalytic member of the -secretase 
complex, is involved in the Notch signaling pathway [44] 
and knocking out PS1 causes embryonic lethality [45]. 
While mice showing reduced PS expression and conditional 
neuronal knockouts are viable, they exhibit behavioral defi-
cits [46, 47] and a report indicates that they may have poten-
tial for initiating tumorigenesis [48]. In the case of -
secretase, a potential treatment strategy would be to enhance 
the cleavage activities of this enzyme. However, such an 
approach is perceived to be more challenging that inhibiting 
cleavage by the pro-amyloidogenic secretases (reviewed in 
[49]).  
BACE1 KNOCKOUTS  
For the development of useful, safe BACE1 inhibitors, 
understanding the function (s) of BACE1 in vivo is critically 
important. Not only has data derived from BACE1
-/- mice 
provided unequivocal proof that BACE1 is the major brain 
-secretase, but it has also
 been used to determine whether 
BACE1 has any vital function in vivo, or if it is dispensable. 
Initial data indicated that the lack of BACE1 expression 
did not appear to adversely affect embryonic development, 
nor did it significantly affect the morphology, physiology, 
biochemistry, and gross behavior of post-natal or adult 
knockout mice [50, 51]. Investigations of BACE1
-/-  mice 
brain function established that no demonstrable differences 
existed, as compared to wild-type mice. Overall these early 
findings indicated that the absence of BACE1 is well toler-
ated in vivo and does not appear to cause untoward effects in 
the developing, post-natal, or adult mouse. 
Data generated from BACE1-deficient mouse models 
was unanimous in demonstrating that -secretase activity is 
abolished in brains and cultured neurons of BACE1
-/- mice. 
Unlike wild-type mice, which make low levels of endoge-
nous A, transgenic (Tg) mice overexpressing human APP 
with the Swedish mutation (Tg2576; [52]) produce robust 
levels of brain A and develop A plaques with age. Impor-
tantly, BACE1
-/-•Tg2576 bigenic mice lacked all forms of 
A, as well as APPs and C99, as compared to BACE1
+/-
•Tg2576 or BACE1
+/+•Tg2576 mice [50]. Thus all products 
of APP processing by -secretase, including A, were abol-
ished in BACE1
-/- brain, unequivocally proving that BACE1 
is the major, if not only, -secretase responsible for A gen-
eration in the brain. In vitro data from BACE1
-/- primary 
neurons and brain tissue added further support for the pre-
dominant role of BACE1 in A generation [51, 53]. BACE1
-/- 
•Tg2576 mice not only lack cerebral A, but also fail to de-
velop amyloid plaques with age [54]. In contrast to Tg2576 
mice that begin to deposit brain amyloid at ~9-12 months, 
BACE1
-/-•Tg2576 bigenic mice show no evidence of amy-
loid deposits even by 13 months. Similar results were ob-
tained using different BACE1
-/- and APP Tg mice [55]. 
These results demonstrate BACE1 is essential for amyloid 
formation. 
Multiple A species, including extracellular fibrillar A, 
intracellular and soluble, oligomeric A, accumulate in AD 
brain [56, 57]. We have recently conducted studies to deter-
mine whether BACE1 deficiency, and the consequent abla-
tion of A, is sufficient to rescue memory deficits in Tg2576 
mice [58]. Tg2576 mice develop memory impairments at an 
early age before the onset of amyloid deposition [59], and 
we chose to study young pre-deposit mice to analyze the 
contribution of soluble A to memory dysfunction. We dem-
onstrated that memory deficits and cholinergic dysfunction 
in the hippocampus did not develop in BACE1
-/-•Tg2576 
bigenic mice that lacked A, while florid deficits were ap-
parent in A-overproducing Tg2576 monogenics. At the 
time of testing the A in Tg2576 mice was non-fibrillar and 
soluble, thus we concluded that soluble A assemblies rather 
than amyloid plaques are responsible for at least some as-
pects of AD-related memory deficits. Our work is further 
validation of BACE1 as a prime therapeutic target for AD 
and provides direct evidence for the amyloid hypothesis in 
vivo.  
Clearly, the consequences of BACE1 ablation in aged 
animals, which exhibit significant amyloid pathology, should 
also be closely examined. To this end, studies involving the 
use of APP/PS1 double Tg mice, which exhibit accelerated 
A accumulation and AD-associated memory deficits as 
compared to single Tg mice, have been performed. While the 
water maze learning was impaired in aged APPswe;PS1E9 
Tg mice, which display abundant amyloid pathology, APP-
swe;PS1E9 lacking BACE1 performed as well as wild type 
controls [55]. Amyloid pathology was not detected in the 
APPswe;PS1E9;BACE1
-/- mice, thus demonstrating that 
BACE1 deletion abolishes amyloid deposition and prevented 
spatial reference memory deficits in aged APPswe;PS1E9 
mice. Similar data was derived from our 5XFAD APP/PS1 
Tg mouse model [60-62]. 5XFAD mice co-express an APP 
transgene carrying the Swedish (K670N, M671L), London 
(V717I) and Florida (I716V) mutations and a PS1 transgene 
carrying double FAD mutations (M146L and L286V; [60]. 
5XFAD mice exhibit aggressive pathology with plaque 
deposition occurring at 2 months and, unlike many Tg mod-
els of AD, exhibit significant neuronal loss in AD-sensitive 
brain regions [60]. The deficits in hippocampus-dependent 
temporal associative learning found in 5XFAD mice were 
rescued in BACE1
-/-;5XFAD mice [61] reviewed in [63]. 
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mice reduced to wild type control levels in BACE1
-/-; 
5XFAD bigenic mouse brain, but the genetic abrogation of 
BACE1 also prevented neuronal loss [62]. These data pro-
vide strong support for the role of A peptides in age-
associated cognitive impairments, and also indicate that A 
is ultimately responsible for neuronal death, at least in Tg 
models of AD. 
Although the initial studies of BACE1 knockout mice did 
not reveal gross alterations in behavior, recently, more pre-
cise behavioral phenotyping studies of BACE1
-/- mice have 
revealed abnormalities in cognitive and emotional functions, 
suggesting potential mechanism-based toxicities resulting 
from complete BACE1 inhibition [55, 58, 61]. We showed 
that BACE1
-/- mice were impaired in both spatial and refer-
ence memories. These mice also exhibited impairments in 
temporal associative memory although they appeared normal 
in social recognition. These data raise the possibility that 
BACE1 is required for some normal hippocampal memory 
processes [58, 61]. Consistent with our findings, Laird [55] 
reported that mice deficient in BACE1 exhibited impaired 
spatial reference and working memories. 
In addition to the putative effect of complete BACE1 ab-
lation on specific cognitive functions, recent findings have 
indicated that BACE1 deficiency might be associated with a 
higher mortality rate in early life [64]. BACE1
-/- mice also 
exhibited other learning-unrelated phenotypes, appearing 
hyperactive, with enhanced locomotion [55, 64]. BACE1
-/- 
mice spent more time in central parts of the open-field and 
visited open-arms in the plus-maze test more often than wild 
type controls, indicating that BACE1 may play some role in 
emotion [55]. However, the putative role that BACE1 may 
play in emotion appears complex. In contrast to Laird [18], 
Harrison and colleagues previously reported that BACE1
-/- 
mice showed timid, more anxious behavior [65]. While 
strain differences may account for these apparently contrast-
ing data, the exact reasons underlying these opposing effects 
of BACE1 on emotion remain to be determined.  
Interestingly, Singer and colleagues demonstrated that a 
partial reduction in BACE1 can improve amyloid neuropa-
thology including the deposition of A, alongside cognitive 
deficits in APP Tg mice [66]. Indeed, comparison of BACE1 
homozygous and heterozygous (BACE1
+/-) knockout mice 
indicated that BACE1
+/- mice exhibited normal spatial mem-
ory function compared to BACE1
-/-  mice, suggesting that 
partial inhibition of BACE1 may not affect normal
 learning 
and memory processes. Such information is of crucial impor-
tance given the fact that when suitable BACE1 inhibitors are 
developed, it will be almost impossible to completely sup-
press BACE1 enzymatic activity in vivo. In this regard, Laird 
demonstrated that A burden appears sensitive to BACE1 
dosage in young animals, with A levels reduced to ~60-
70% in APPswe;PS1E9; BACE1
+/-  compared to age-
matched APPswe;PS1E9 animals [55]. However, the A 
burden was not altered in older mice, despite the same de-
crease in BACE1 levels, indicating that BACE1 is no longer 
a limiting factor in the aged mouse. Consistent with these 
findings was that older APPswe;PS1E9; BACE1
+/-  mice
 
were significantly impaired in the Morris water maze, indi-
cating that 50% reductions in BACE are not sufficient to 
significantly ameliorate cognitive deficits in aged mouse in 
contrast to complete BACE1 ablation. Although further work 
is required, these data indicate that a partial suppression of 
BACE1 may have the most benefit for the earlier phases of 
A-dependent cognitive impairments. However, the age-
dependent benefits of partial reduction BACE1 expression 
appear complicated. McConlogue and colleagues recently 
reported that, in contrast to the observations of Laird, a 50% 
decrease in BACE1 levels exerts little impact on A levels in 
young APP Tg mice, but led to a dramatic reduction in A 
levels and synaptic deficits in aged mice [67]. The reasons as 
to why these findings appear discordant with those of the 
previous study remain to be determined, but may be due to 
the expression of different APP moieties, APP with the 
Swedish mutation [55] vs. APP with the V717F mutation 
[67]. The Swedish mutation enhances the cleavage of APP 
by BACE1. As McConlogue and colleagues discuss, the co-
expression of APPswe with the PS1 transgene in the Laird 
study led to an aggressive model of plaque development that 
may somehow impact the sensitivity of APP metabolism to 
alterations in BACE1 levels. 
Despite the apparent benefits of a reduction in BACE1 
levels reported above, there has been a recent study that con-
tains data that may be a cause for some concern. While the 
BACE1-mediated cleavage of APP is predominantly re-
garded as a negative process, Ma and colleagues reported the 
facilitation of learning, memory and synaptic plasticity by 
this cleavage event [68]. In this study, APP-overproducing 
mice exhibited enhanced spatial memory rather than AD 
pathology or memory deficits. Interestingly, a significant 
decrease in AICD (but not of any other APP cleavage prod-
ucts) abolished the enhanced synaptic plasticity and memory. 
The authors propose that these data indicate that normal 
brain functions are facilitated by the regulated, activity-
dependent cleavage of APP by BACE1 in neurons. Impor-
tantly, AICD levels decreased significantly in both BACE1 
heterozygous and null mice and it was noted that the removal 
of one BACE1 gene dramatically reduced AICD without 
altering other APP cleavage product levels. As discussed by 
Ma and colleagues, these data stress the requirement for 
thorough preclinical studies of experimental BACE1 inhibi-
tors, not only in animal models of AD, but also in wild type 
animals to evaluate their effect on normal cognitive function-
ing [68]. These data await confirmation from other studies. 
In conclusion, the lack of A generation in the brains of 
BACE1 deficient mice indicates that therapeutic inhibition 
of BACE1 should reduce cerebral A levels and amyloid 
development, an outcome likely to be beneficial for AD. 
While recent studies indicate that complete blockage of 
BACE1 activity may be associated with certain undesirable 
side-effects, important data demonstrates that partial reduc-
tion of BACE1 levels may improve cognitive deficits and 
amyloid neuropathology including A deposition, at least in 
specific AD Tg models. However, given that AICD may be 
required for normal memory, the degree of BACE1 inhibi-
tion required to have beneficial lowering effects on A levels 
without impacting AICD levels remains to be determined. 
BACE2: MORE LIKE - THAN -SECRETASE 
Due to redundancy, the lowering or removal of one 
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other. Clearly, data from BACE1
-/- mice unequivocally prove 
that BACE1 is the -secretase responsible for A generation. 
However, BACE2, a BACE1 homologue, has been identi-
fied. It was plausible that knowledge of homologous BACE1 
proteins may prove useful for the determination of the 
BACE1 function in vivo. Indeed, given that BACE1 mRNA 
[28, 69] and protein [70] are detected at high levels in brain 
areas that are devoid of APP and which have very low A 
plaque counts, such as the striatum and thalamus, alternative 
BACE1 substrates in different brain regions may exist, as 
discussed later.  
BACE2 is mapped to the DS critical region on chromo-
some 21 [71, 72]. The amino acid sequences of BACE1 and 
BACE2 are ~45% identical and 75% homologous [73]. 
Overall the BACE2 structure contains features typical of this 
protease family. BACE1 and BACE2 have distinct transcrip-
tional regulation and function [73]. BACE2 mRNA has been 
observed at low levels in most human peripheral tissues. 
However, unlike BACE1, which is enriched in neuronal 
populations [19], human adult and fetal whole brain express 
very low or undetectable levels of BACE2 mRNA [28, 74]. 
In vitro, BACE2 can cleave APP at the -secretase cleavage 
site [75, 76] and BACE2 appears to be primarily responsible 
for A production in Flemish mutant APP transfected cells 
[75]. However, other studies have demonstrated that BACE2 
functions as an alternative -secretase and as an antagonist 
of BACE1 [77, 78]. BACE2 does not get upregulated to 
compensate for a lack of BACE1 in knockout mice [54]. 
Further evidence that BACE2 functions not as a -secretase 
comes from a recent study which identifies BACE2 as a 
novel theta ()-secretase. Radiosequencing clearly demon-
strated that the major BACE2 cleavage site is between 
Phe+19 and Phe+20 sites of APP [79, 80], thus BACE2 
cleaves APP at a novel -site downstream of the -secretase 
cleavage site [81]. Cleavage of APP by BACE2 at this site 
abolishes A production. Furthermore, overexpression of 
BACE2 reduced A production in primary neuronal cultures 
derived from APP transgenic (Tg) mice [81]. 
BACE1 GENE 
Given that the -secretase gene is a strong candidate gene 
for LOAD because of its function in initiating A produc-
tion, and that the etiology of the disease remains unknown, 
the genomic organization of the BACE1 gene and the pres-
ence of polymorphisms have been closely examined. The 
BACE1 gene spans ~30 kilobases on human chromosome 
11q23.2 and includes 9 exons. The data regarding the asso-
ciation between polymorphisms in BACE1 and AD were 
initially mixed, although more recent findings from a num-
ber of groups concur that polymorphisms in exon 5 of 
BACE1 are associated with AD. Murphy and colleagues [82] 
identified two polymorphisms in exon 5 and intron 5 of the 
BACE1 gene. However, neither appeared to be associated 
with AD risk in genetic association studies comparing late-
onset AD cases (autopsy-confirmed) with age-matched non-
demented controls. Nevertheless, Nowotny reported that 
there was a weak association between the BACE1 exon 5 
polymorphism and AD in those carrying the ApoE4 allele 
[83]. Indeed, a later study that analyzed three polymorphisms 
located at the BACE1 gene, found an association between 
BACE1 exon 5 GG genotype and AD. The authors state that 
in combination with earlier results, there is a clear increase in 
the risk of developing AD in subjects carrying both the 
BACE1 exon 5 GG genotype and the ApoE4 allele [84]. 
Kirschling and co-workers reported that the BACE1 exon 5 
polymorphism influenced AD risk and that this effect was 
indeed most pronounced in ApoE4 allele carriers [85]. Fur-
thermore, while initial genotype data from a late-onset AD 
group and a control cohort failed to demonstrate any associa-
tion between BACE1 and AD, following stratification for 
ApoE status it was concluded that a combination of a spe-
cific BACE1 allele (within BACE1 codon V262) and ApoE4 
may increase AD risk over that attributed to ApoE4 alone 
[86]. A very recent meta-analysis study investigating AD 
association with BACE1 exon 5, demonstrated that the geno-
type CC+CT acts as a protective factor in ApoE4 carriers, 
and as a risk factor in apoE4 non-carriers [87]. To date the 
mechanisms that underlie the associations of BACE1 exon 5 
polymorphisms with AD remain to be established.  
Importantly, a recent study has highlighted the feasibility 
of the ultra-high density whole-genome association approach 
to the study of AD. Indeed predictions are that such ap-
proaches show potential for the future identification of addi-
tional genes that contribute to AD [88]. Clearly, the ApoE4 
allele is a well-established risk factor for sporadic AD. How-
ever, this locus on chromosome 19 was not identified in ini-
tial genome scans using microsatellite markers in late-onset 
AD. However, ultra-high density single nucleotide polymor-
phisms (SNP) genotyping (a method to simultaneously as-
sess hundreds of thousands of SNPs) precisely identified the 
ApoE locus as being significantly associated with late-onset 
AD (Coon et al., 2007). As no other SNP showed such as 
robust an association these data support the indisputable no-
tion that the epsilon 4 variant of ApoE is the biggest genetic 
risk factor for LOAD. 
THE CELL BIOLOGY OF BACE1  
To gain insight into the regulation of BACE1 and iden-
tify other potential therapeutic targets in the -secretase 
pathway, groups began investigating the cell biology of 
BACE1. BACE1 is initially synthesized in the endoplasmic 
reticulum (ER) as an immature precursor protein (pro-
BACE1) with a molecular mass of ~60kDa [39, 89-91]. Site-
directed mutagenesis indicates that acetylation of seven ly-
sine residues of the N-terminal portion of nascent BACE1 is 
required for the protein to leave the ER and to progress 
through the secretory pathway [92]. ProBACE1 is short-
lived and undergoes rapid maturation into a 70kDa form in 
the Golgi, which involves the addition of complex carbohy-
drates and the removal of the propeptide domain.  
BACE1 is glycosylated at four N-linked sites [39], a 
modification which affects the protease activity of the en-
zyme since abolishing two out of four N-linked sites by site-
directed mutagenesis significantly reduces -secretase activ-
ity [93]. Mature N-glycosylated moieties of BACE1 are sul-
fated and three cysteine residues within the cytosolic tail of 
BACE1 are palmitoylated, which might influence intracellu-
lar localization or trafficking [38]. The BACE1 propeptide 
domain is removed within the Golgi apparatus by cleavage 
between Arg45 and Glu46 [74]. While the majority of aspar-
tic proteases, including BACE2, cleave the propeptide do-514    Current Genomics, 2007, Vol. 8, No. 8  Cole and Vassar 
main autocatalytically in response to changes in pH or ionic 
strength [94], BACE1 propeptide removal involves intermo-
lecular cleavage by a different protease. Furin, a ubiquitous 
Golgi-localized proprotein convertase (PC) appears to be the 
major protease mediating BACE1 propeptide removal, al-
though other PCs are also capable of cleaving the BACE1 
propeptide [38, 74, 91]. Unlike other zymogens, proBACE1 
exhibits robust -secretase activity, suggesting that the 
BACE1 propeptide domain does not suppress protease activ-
ity significantly [38, 91]. Indeed, proBACE1 may cleave 
APP early in the biosynthetic pathway leading to the genera-
tion of an intracellular pool of A in the ER, thought by 
some investigators to be particularly neurotoxic [91]. Fol-
lowing maturation, the lysine residues are deacetylated in the 
Golgi lumen [92]. Mature BACE1 localizes largely within 
cholesterol-rich lipid rafts [95, 96], and is quite stable, hav-
ing a half-life of over nine hours in cultured cells. 
In cultured polarized cells such as neurons or Madin-
Darby canine kidney cells, BACE1 is predominantly trans-
ported to the axonal/apical compartment, while APP and -
secretase are sorted mainly to the somatodendritic/basola- 
teral compartment [97]. This trafficking pattern is consistent 
with observations in vivo indicating that BACE1 is trans-
ported down axons of the perforant pathway [98] and that 
axon terminals may be major sites of A production [98, 99]. 
Further data about the subcellular trafficking and localization 
of BACE1 is detailed later. 
Although the majority of BACE1 in cells is produced as 
an integral membrane protein, a small fraction of BACE1 
undergoes ectodomain shedding, a process that is suppressed 
by palmitoylation [38]. Inhibition of shedding does not in-
fluence processing of APP at the -site [100]. However, co-
expression of APP and the soluble ectodomain of BACE1 in 
cells increases the generation of A, suggesting the enhanced 
BACE1 ectodomain shedding may raise amyloidogenic 
processing of APP [38]. Murayama and colleagues reported 
the release of detectable levels of BACE1 holoprotein in 
vitro [101], although the physiological relevance of this 
event remains to be clarified. Interestingly, active, soluble 
BACE1 has been detected in human cerebral spinal fluid 
(CSF), [102], a finding which raises the potential use of 
BACE1 detection in an easily accessible biological fluid, 
such as CSF, in diagnostic or prognostic applications in the 
future. 
BACE X-RAY STRUCTURE 
Structural information about the interaction of substrate 
with the active site of BACE1 would greatly facilitate the 
rational design of small molecule BACE1 inhibitors. Mo-
lecular modeling was used to simulate the BACE1 active site 
bound with wild-type or mutant APP substrates [103], and 
several residues that potentially contribute to substrate speci-
ficity in BACE1 were identified. Shortly afterwards, the x-
ray structure of the BACE1 protease domain co-crystallized 
with a transition-state inhibitor was determined to 1.9 ang-
strom resolution [104]. As expected, the BACE1 catalytic 
domain is similar in structure to pepsin and other aspartic 
proteases, despite the relatively low sequence similarity. 
Interestingly, the BACE1 active site is more open and less 
hydrophobic than that of other aspartic proteases. Four hy-
drogen bonds from the catalytic aspartic acid residues 
(Asp93 and Asp289) and ten additional hydrogen bonds 
from various residues in the active site are made with the 
inhibitor, most of which are conserved in other aspartic pro-
teases. The x-ray structure indicates that Arg296 and the 
hydrophobic pocket of the active site play an important role 
in substrate binding, confirming the results of the molecular 
modeling study. In addition, the bound inhibitor has an un-
usual kinked conformation from P2’ to P4’. The kink di-
rected residues P3’and P4’ toward the protein surface have 
little protein-inhibitor interaction, suggesting the absence of 
S3’ and S4’ subsites in BACE1. However, subsequent crys-
tal structure of OM00-3 binding to BACE1 showed clear 
interaction at these two positions and thus identified the lo-
cation of these two subsites on the protease [105]. The 
BACE1 X-ray structure suggests that small molecules target-
ing Arg296 and the hydrophobic pocket residues should in-
hibit -secretase cleavage. Moreover, mimicking the unique 
P2’-P4’ conformation of the bound inhibitor may increase 
the selectivity of inhibitors for BACE1 over BACE2 and the 
other aspartic proteases. 
BACE1 SUBSTRATES 
BACE1 is crucial for A generation, and the normal pro-
duction of A in the brain raises the possibility that rather 
than being a toxic by-product of APP metabolism, A may 
fulfill a regular physiological function. Indeed, our examina-
tion of BACE knockout mice indicated that complete abro-
gation of A was associated with impaired memory per-
formance, data suggestive of a role for A in normal mem-
ory [58]. These data were consistent with earlier reports of a 
potential physiological role of A in normal neuronal func-
tion [46, 106]. Indeed, a recent report suggests that the pro-
duction of endogenous A is an important physiological 
regulator of potassium channel expression and negatively 
modulates neuronal excitability [107]. However, our data 
indicate that BACE1 deficiency does not impact all types of 
hippocampal learning [58] and it is clear that further work is 
required to examine the putative normal role of A in vivo, 
under non-pathological conditions.  
In addition to APP, BACE1 also cleaves the APP homo-
logues, amyloid precursor-like proteins, APLP1 and APLP2 
[108, 109]. While APLP1 and APLP2 lack the A sequence, 
relatively little else is known about these proteins, although 
it is known that the APLPs can be processed by -secretase 
generating intracellular fragments with potential transcrip-
tional activity [110, 111]. 
Given the fact that the majority of APP molecules are 
cleaved by -secretase moieties, with only a small fraction 
being BACE1 substrate, it is highly likely that other BACE1 
substrates exist. While the essential cellular functions of 
BACE1 under normal conditions have proved somewhat 
elusive, recent findings have started to define a physiological 
function for this enzyme.  
BACE1 is enriched in neuronal populations, and -
secretase processing of APP is modulated by the interaction 
of BACE1 with neurite growth inhibitor NOGO, a compo-
nent of myelin, and a member of the reticulon family of pro-
teins [112]. Indeed, BACE1 interacts with all members of 
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for BACE1 in axonal growth and brain development has 
been recently proposed, whereby BACE1 regulates the mye-
lination process in both peripheral and central nerves [114, 
115]. The neuronal type III isoform of the epidermal growth 
factor (EGF)-like factor neuregulin 1 (NRG1) regulates mye-
lination and is a known initiator of peripheral nervous sys-
tem (PNS) myelination and a modulator of myelin sheath 
thickness in both the central nervous system (CNS) and the 
PNS. BACE1 is transported to axons by a kinesin-1-
dependent pathway [116] and the highest levels of BACE1 
expression are observed when myelination occurs during the 
early postnatal stages [115]. In situ hybridization revealed 
co-expression of BACE1 with type III NRG1 within sensory 
and motor neurons whose axons project within peripheral 
nerves. Importantly, data generated from BACE1 null mice 
showed that the absence of BACE1 was associated with hy-
pomyelination of both CNS and PNS axons.  
Interestingly, previous reports indicated that mice defi-
cient in BACE1 exhibit altered hippocampal synaptic plas-
ticity and decreased cognitive function [55, 58, 61] reviewed 
in [63]. Indeed, specific neurological impairments were as-
sociated with the genetic ablation of BACE1 in this myelina-
tion study [114]. At the molecular level, BACE1
-/- brain, 
when compared to wild type brain, accumulated uncleaved 
NRG1 and exhibited reduced levels of NRG1 cleavage 
fragments, findings consistent with a role for BACE1 in the 
proteolysis of NRG1 [114, 115]. It should be noted that 
complete deletion of BACE1 was necessary in order to alter 
the signaling events and cause hypomyelination. In agree-
ment with some (but not all [68]) previous findings that par-
tial BACE1 inhibition may be without effect on normal 
learning and memory processes, [55] reviewed in [63], 
BACE
+/- mice did not display any of the biochemical and 
morphological features observed in the BACE1 null mice.  
It is known that synaptic dysfunction precedes overt neu-
rodegeneration in AD development. Research supports the 
notion that BACE1 cleaves APP to generate A in the syn-
aptic terminal [98, 99]. Several additional, non-APP BACE1 
substrates have recently been identified, some of which may 
be localized at the terminal, suggesting that BACE1 cleavage 
of particular substrates may be required for normal function 
at the synapse.  
Voltage-gated sodium channels (VGSC; Nav) are abun-
dant ion channels responsible for the initiation and propaga-
tion of action potentials. These channels are complexes con-
sisting of  and  subunits. Although not essential for the 
basic VGSC functioning, the VGSC subunits are important 
auxiliary units. Expression of both subunit types is required 
for full VGSC functionality. Importantly, VGSC subunits 
are BACE1 substrates, and BACE1 cleavage generates a 
membrane-bound -CTF [117, 118]. Furthermore, analogous 
to APP processing, VGSC subunits are processed further by 
-secretase, which generates an 2-intracellular domain (2-
ICD; [118]). The functional ramifications of these cleavage 
events have been recently elucidated. 2-ICD regulates ex-
pression of the  subunit, Nav1.1. Importantly, the increased 
pool of Nav1.1 is maintained within the cell and the BACE1 
cleavage of the 2 subunit actually leads to loss of functional 
membrane channels, a reduction in Na
+ current and altera-
tions in membrane excitability [118]. Importantly, the proc-
essing of VGSC2 and VGSC4 by BACE1 has been dem-
onstrated in vivo and elevated 2-CTF and Nav1.1 were ob-
served in human AD brain tissue [117, 118]. Neural activity 
regulates A production through - and -secretase and syn-
aptic transmission and neuronal activity is depressed by A 
[106, 119]. It is thus plausible that the turnover of mem-
brane-localized functional sodium channels by the sequential 
processing by BACE1 and -secretase in wild type neurons 
may play a role in such a feedback mechanism as to modu-
late neuronal activity and endogenous A production. In 
addition, processing of VGSC4 by BACE1 may also regu-
late the filopodia-like protrusion density in neurons together 
with neurite length [120].  
The proteolytic processing of membrane proteins to their 
soluble counterparts during ectodomain shedding is an im-
portant step in regulating the biological activity of membrane 
proteins. Ectodomain shedding is carried out by members of 
the ADAM family, and to a lesser extent by BACE (re-
viewed in [121]). This is the first event in a two-step prote-
olytic cleavage event known as regulated intramembrane 
proteolysis (RIP). Subsequently, the resulting membrane 
bound CTF, undergoes a second cleavage within its trans-
membrane domain, called intramembrane proteolysis. APP 
undergoes RIP by the - and -secretases, with the intram-
embrane proteolysis being catalyzed by the -secretase com-
plex. Indeed, studies have proposed that other BACE1 sub-
strates may be found among proteins undergoing ectodomain 
shedding, as discussed below.  
Another putative BACE1 substrate with a proposed neu-
ronal function, which also undergoes ectodomain shedding, 
is the lipoprotein receptor-related protein (LRP). Accumulat-
ing evidence indicates that elevated cholesterol might be 
closely involved in AD development. LRP is a type I integral 
membrane protein which functions as a multifunctional en-
docytic receptor and has been implicated as having signaling 
roles in neurons [122]. Furthermore, LRP appears to be inti-
mately associated with AD pathology and previous reports 
have implicated LRP in the mediation of endocytosis of a 
number of important AD-linked ligands including APP and 
ApoE. Indeed, it has been shown that LRP regulates A traf-
ficking, binds A complexes and mediates its degradation. In 
vivo, the absence of LRP in the presence of APP overexpres-
sion led to a two fold increase in amyloid deposition, find-
ings supporting the notion that the LRP might play an inte-
gral role in A clearance and might be neuroprotective 
against A toxicity [123]. LRP is also processed in manner 
analogous to APP, at least in vitro. Not only is LRP prote-
olyzed by matrix metalloproteases, but the -secretase cleav-
age of LRP enables release of the LRP-intracellular domain 
(LRP-ICD). Furthermore, LRP may be a substrate for 
BACE1 cleavage [124]. Endogenous BACE1 and LRP co-
immunoprecipitate from human brain and it appears as if the 
LRP-BACE1 complexes occur in lipid-rafts, with the closest 
association being at the cell surface. Further in vitro analyses 
demonstrated that endogenous levels of BACE1 activity fa-
cilitated an increase in the secretion of LRP, in addition to 
the formation of the LRP CTF. Moreover, increased BACE1 
expression facilitated an enhancement of -secretase LRP 
cleavage and release of the LRP-ICD. It was also shown that 
LRP competes with APP for -secretase activity [125]. The 
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interact with Fe65 and Tip60, although whether this occurs 
under physiological conditions remains to be determined. 
However, the recent observation that full length LRP1 levels 
were unaltered in BACE1
-/- mice, compared to wild type 
mice has shed doubt as to whether LRP is a true physiologi-
cal substrate of BACE1 [126].  
Neuroinflammation is a pathological feature of AD and 
increasing evidence suggests that neurotoxicity is mediated 
by CNS inflammatory processes whereby A is involved in 
the activation of microglia facilitating the subsequent release 
of inflammatory cytokines including IL-1, IL-6 and TNF-, 
among others (reviewed in [127]). Interestingly, several pu-
tative BACE1 substrates are closely associated with the in-
flammatory response.  
P-selectin glycoprotein ligand 1 (PSGL-1) modulates 
leukocyte adhesion in inflammatory reactions and it was 
determined that cleavage of PSGL-1 by BACE1 liberated 
cleavage products observed in vivo, whereas no PSGL-1 
cleavage fragments were detected in primary cells derived 
from BACE1 deficient mice [128]. A second membrane pro-
tein involved in regulating the immune response also appears 
to be a BACE1 substrate. BACE1 is enriched in neuronal 
Golgi membranes. Beta-galactoside alpha 2,6-sialyltransfe- 
rase (ST6Gal1) is a Golgi-resident sialyltransferase that is 
secreted out of the cell after proteolytic cleavage. BACE and 
ST6Gal I co-localize in the Golgi and BACE1 overexpres-
sion elevates ST6Gal I secretion [129]. Moreover, data from 
mouse models demonstrated that BACE1 cleaves ST6Gal I 
in vivo [130].  
Ectodomain shedding is important in the inflammatory 
response. The interleukin-1 receptor II (IL-1R2) undergoes 
shedding and functions as a decoy receptor thought to limit 
the detrimental effects of IL-1 in the brain. Indeed, increased 
proteolytic processing and secretion of IL-1R2 has been 
linked to AD pathogenesis [131]. Recent data showed that 
IL-1R2 is processed by all three secretase moieties in a man-
ner analogous to APP [132], and IL-1R2 secretion was ele-
vated by BACE overexpression. Cleavage of IL-1R2 by both 
BACE enzymes occurred at sites that agreed well with the 
known cleavage specificity of BACE1 and BACE2 and led 
to the generation of CTF that were similar to those generated 
by -secretase cleavage. It is noteworthy that in addition to 
IL-1R2, the processing of the type I membrane protein, 
TGF and the GPI-anchored protein CD-16 was also ele-
vated upon overexpression of the BACE enzymes. Interest-
ingly, in contrast to other BACE substrates, the cleavage of 
IL-1R2 (and TGF and CD-16) was not reduced in BACE
-/- 
cells. The authors argued against the fact that IL-1R2 may 
not be a physiological substrate of BACE by focusing on the 
BACE cleavage site of IL-1R2. BACE1 and BACE2 cleaved 
IL-1R2 only 4 amino acids away from the -secretase cleav-
age site, so close that the -secretase and BACE IL-1R2 
CTFs would be very similar in size and likely impossible to 
resolve using electrophoresis. Thus, a decrease in BACE IL-
1R2 cleavage would be compensated for by an increase in -
secretase cleavage and thus no net change in total IL-1R2 
would be observed. Indeed, this is a valid point and, as the 
authors suggest, if BACE cleavage occurs close to the cleav-
age sites of specific substrates, such as TGF and CD-16, by 
other proteases, it may be particularly challenging to une-
quivocally identify a specific protein as a novel BACE sub-
strate. Thus in addition to IL-1R2, it may be the case that the 
BACE enzymes also have a more general role as alternative 
-secretase-like proteases and are involved in the shedding 
of additional type I, II and GPI-anchored proteins known to 
undergo ectodomain shedding. In comparison to the large 
number of ADAM proteases, BACE1 and 2 are expressed at 
low levels. Thus if these proteases do act as alternative -
secretase moieties in vivo, their loss of expression could be 
compensated for by the ADAM proteases, which have par-
tially redundant functions. Consequently, BACE knockouts, 
unlike ADAM protease knockouts, may exert more subtle, 
rather than striking, phenotypes, as demonstrated.  
The BACE1 substrates identified to date are all localized 
to the membrane and it has been previously suggested that 
BACE1 exerts a generalized role in the secretion of mem-
brane proteins. However, Kuhn and colleagues investigated 
BACE cleavage specificity and observed that BACE did not 
cleave a number of membrane proteins including TNF, P-
selectin and CD14, suggesting that the proteases did not 
simply contribute to general membrane protein turnover 
[132].  
BACE1 INCREASES IN AD 
A plays a central role in AD pathogenesis. A levels in-
crease with age and excessive A deposition occurs in AD. 
In FAD and DS, A deposition can be attributed to excessive 
A production mediated by APP/PS1 mutations or APP gene 
dosage effects. The mechanism by which excessive A ac-
cumulation occurs in LOAD remains unclear. Reduced A 
clearance and/or degradation is one potential mechanism 
leading to increased cerebral A levels in AD. However, it is 
also possible that small increases in A production over time 
may tip the balance toward A accumulation. BACE1 is 
critical for A biosynthesis and it is likely that factors that 
elevate BACE1 may lead to increased A generation and 
promote AD. Indeed, FAD cases caused by the APP Swedish 
mutation, which enhances cleavage by BACE1, imply that 
increased BACE1 activity may be sufficient to induce AD 
pathogenesis. Furthermore, several recent reports have indi-
cated that BACE1 dysregulation maybe involved in AD 
pathogenesis. 
An age-related increase in BACE1 activity in mouse, 
monkey and non-demented human brain has been reported 
[133]. The increased activity appeared independent of brain 
region and although levels of BACE1 protein remain un-
changed, there was a positive correlation between elevated 
BACE1 activity and increased A levels in mouse and hu-
man brain regions.  
Furthermore, significant increases in BACE1 protein and 
activity have been observed in the AD brain. In high-order 
association brain regions affected by A deposition BACE1 
protein levels and activity were increased significantly in AD 
brain compared to non-demented control brain [134-138]. 
Given the competition for APP substrate, it is interesting to 
note that, in addition to increased BACE1 activity, a study 
demonstrated that in approximately two thirds of samples 
studied, -secretase activity was decreased in AD temporal 
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percent of AD brains examined had an increase in BACE1 
activity, a decrease in -secretase activity, or both [135]. 
Neuronal loss is a key feature of late-stage AD and thus, 
it is crucial that protein level and activity measurements are 
normalized to neuronal markers. Interestingly, the measures 
of BACE1 protein and activity levels were even more pro-
nounced in AD brain when normalized to the synaptic 
marker, synaptophysin [134]. The significance of normaliza-
tion to neuron-specific markers is further underscored by the 
findings of Harada that, in contrast to the above study, indi-
cated that total BACE1 levels in AD temporal cortex was not 
increased [139]. However, the ratio of BACE1 protein to 
specific neuronal markers was significantly increased, indi-
cating that the surviving neurons in AD brain may express 
higher BACE1 levels than those observed in neurons from 
control brain. 
Although Fukumoto observed no significant correlation 
between elevated BACE activity and A load in AD tempo-
ral cortex [134], measurements of total A were taken rather 
than identifying the levels of specific A species. However, 
Li and colleagues reported that the observed elevation of 
BACE activity is correlated with brain A1-x and A1-42 
levels production in the frontal cortex [138], suggesting that 
indeed, BACE1 elevation may lead to enhanced A produc-
tion and deposition. Interestingly, a significant correlation 
between BACE1 levels and plaque load in AD brains was 
observed [137, 138]. 
BACE1 increases have also been observed in DS. People 
with DS inevitably develop characteristic AD neuropathol-
ogy. However, APP gene dosage alone may not fully ac-
count for the AD pathology in DS [140]. Recently, a novel 
molecular mechanism by which AD may develop in DS has 
been proposed. Analysis of fetal DS and normal cerebral 
cortex indicated an elevation of C99, A40 and A42 in the 
trisomic tissue. The data indicated that the increase in APP 
level only partially contributed to A over-generation in DS. 
Furthermore, the DS tissue showed a significant increase in 
the levels of total BACE1 protein, in particular mature 
BACE1 [141]. Importantly, subcellular fractionation of nor-
mal and DS brain tissue showed the marked accumulation of 
mature BACE1 in the Golgi fraction of DS cells. The authors 
proposed that the higher levels of mature BACE1 in DS tis-
sue result in higher BACE1 activity leading to elevated C99 
and A production. The cause of the BACE1 elevation in DS 
remains to be determined. 
Because aging is the strongest risk factor for AD, and 
BACE activity increases with age and to an even greater 
extent in LOAD, AD may reflect an exaggeration of age-
related changes in BACE1 activity. Despite normalization of 
BACE1 levels to synaptic markers in AD brain, it remains 
difficult to determine from postmortem brain whether a spe-
cific change is an epiphenomenon in late-stage AD, or 
whether it is an early event directly involved in pathogenesis. 
Indeed, many biochemical parameters deviate from normal 
in AD and a recent proteomic study estimated that ~100 dif-
ferent proteins have deranged levels or abnormal modifica-
tions in AD (reviewed in [142]). To address whether the 
BACE1 elevation observed in AD brain is merely a passive 
end product of advanced neurodegeneration and cell death or 
whether it is actively involved in disease progression, we 
examined BACE1 levels in two Tg models of AD [143], 
namely the 5XFAD mouse [60] that develops amyloid 
plaques at young ages and exhibits significant neuronal loss, 
and the Tg2576 mouse [52], which develops plaques at older 
ages and does not show neuronal death. In contrast to human 
brain tissue, these Tg lines allow analysis of the effects of 
amyloid pathology on BACE1 elevation in the presence or 
absence of cell death [143]. BACE1 was elevated in the 
brains of both Tg models and AD patients. Importantly, be-
cause the BACE1 increase correlated with amyloid pathol-
ogy in both Tg models and was observed in both the absence 
(Tg2576) and presence (5XFAD) of significant neuronal 
loss, we concluded that BACE1 elevation appeared to be 
associated with amyloid pathology rather than cell death.  
Many BACE1 antibodies are somewhat nonspecific 
[143]. Therefore, we generated a mono-specific BACE1 an-
tibody, BACE-Cat1. BACE-Cat1-immunostaining showed 
the neuronal localization of BACE1, with BACE1 im-
munoreactivity surrounding A42-containing plaque cores in 
both the Tg and AD brain. While further studies are required, 
the co-localization of BACE1 immunoreactivity with synap-
tophysin, but not MAP2, suggested a presynaptic localiza-
tion for BACE1. Interestingly, an earlier study demonstrated 
similar findings [98] and our data suggest that the BACE1 
elevation occurs in presynaptic neuronal structures around 
neuritic plaques and that A42 may cause the increase.  
It is currently unclear whether the BACE1 elevation in 
AD promotes A generation and disease progression. How-
ever, an AD feedback loop has long been surmised and our 
data are suggestive of a positive feedback loop, whereby 
A42 deposition in AD causes BACE1 (and possibly APP) 
levels to rise in nearby neurons. Increased A production 
may then ensue, initiating a vicious cycle of additional amy-
loid deposition followed by further elevated BACE1 levels. 
Given the elevation of BACE1 around A42 plaque cores it 
seems possible that A42 somehow triggers the BACE1 in-
crease. It is well established that A42 is neurotoxic and 
such toxicity may induce the BACE1 elevation. However, it 
remains undetermined as to which is the initiating event, A 
elevation and deposition or increased BACE activity. Inter-
estingly, a study recently proposed that A acts via a bipha-
sic neurotoxic mechanism, which is conformation-depen- 
dent, with A oligomers inducing oxidative stress while fi-
brillar A increases BACE1 expression and activity [144]. 
Nevertheless, it is currently unclear whether such a biphasic 
mode of action occurs in vivo. 
POTENTIAL TRIGGERS FOR BACE1 ALTERA-
TIONS IN AD 
AD pathogenesis is complex and its etiology undeter-
mined. While risk factors for LOAD have been identified, 
the molecular mechanisms that link AD risk factors with the 
pathology of this disease are yet to be clarified. However, we 
do know that alterations in BACE1 (levels and/or activity) 
have been observed in AD and a number of risk factors, 
more over their downstream consequences, can be linked 
with such BACE1 alterations.  
AD and vascular diseases (both cardio- and cerebro-) ap-
pear to be intimately linked. Heart disease and stroke associ-
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with cerebral hypoperfusion (reviewed in [145]). Increasing 
evidence from neuroimaging [146-148] and epidemiological 
studies [149-152] suggests that vascular risk factors and the 
ensuing reduced cerebral blood flow (CBF) and chronic 
brain hypoperfusion (CBH) are key factors in AD develop-
ment and may play a causative role in dementia. Indeed, 
CBH is a preclinical condition of mild cognitive impairment 
(MCI; a condition thought to precede AD) and is an accurate 
indicator for the prediction of AD development [153-157].  
CBH can cause hypoxia, a form of cellular stress, to-
gether with ischemic episodes, which have been reported to 
increase AD risk [158, 159]. Indeed, oxidative stress has 
been implicated in AD pathology [160, 161] and defective 
energy metabolism may play a fundamental role in AD 
pathogenesis. Positron emission tomography imaging indi-
cates that glucose utilization is lower in AD brain than in 
age-matched control brain [162-165], and MCI patients ex-
hibit reduced glucose metabolism [166-168] suggesting that 
insufficient energy metabolism may be a factor in preclinical 
AD. Recently, data has emerged that links A generation 
with cardiovascular disease. Importantly, the downstream 
consequences of vascular insults and the resulting CBH, in-
cluding hypoxia, energy depletion and cellular stress appear 
to increase BACE1 levels and activity [169-175]. The poten-
tial mechanisms of how these cellular alterations could alter 
BACE1 are discussed below. 
PUTATIVE MOLECULAR MECHANISMS REGU-
LATING BACE1 IN AD: THE COMPLEXITY OF 
BACE1 EXPRESSION 
As just discussed, multiple recent studies have reported 
the elevation of BACE1 levels and/or activity in AD brain. 
Understanding the regulation of BACE1 expression may 
illuminate the role of BACE1 in normal biology, identify 
mechanisms that lead to disease, and might suggest ap-
proaches to inhibit BACE1 therapeutically. Here the regula-
tion of BACE1 expression is discussed in detail. It is clear 
that BACE1 expression is regulated in a complex manner, 
both at the transcriptional and post-transcriptional level. We 
have used the latter phrase as an umbrella term to represent 
post-transcriptional processing and modification, mRNA 
stability, translation initiation, post-translational modifica-
tions and protein clearance. Thus, in addition to a number of 
transcriptional factors acting as either activators or repressors 
of BACE1 transcription, alternative splicing events, intracel-
lular signal transduction pathways, post-translational modifi-
cations and alterations in protein half-life can affect the level 
and enzymatic activity of BACE1. Furthermore, BACE1 
interacts with a number of other protein moieties, many of 
which are involved in protein trafficking, and so alterations 
in the level of these proteins may in turn affect BACE1 lev-
els, subcellular localization and/or activity. It should be 
noted that the various AD risk factors discussed previously 
might impact BACE1 levels in a variety of ways, both at the 
transcriptional and post-transcriptional levels. 
TRANSCRIPTIONAL REGULATION OF BACE1 EX-
PRESSION 
In order to gain insight into the regulation of BACE1 
gene expression, both the human and rodent BACE1 gene 
promoters have been sequenced and analyzed [176-179]. 
Indeed, the BACE1 promoter is highly conserved between 
rodents and humans [176, 177] indicating that regulatory 
mechanisms of BACE1 expression are shared between these 
species and that rodents represent useful models in which to 
study mechanisms and to test therapeutics aimed at reducing 
BACE1 expression.  
The BACE1 gene promoter lacks the typical CAAT and 
TATA boxes, but contains six unique functional domains 
and three structural domains of increasing sequence com-
plexity as the ATG start codon is approached [180]. It also 
contains a variety of transcription factor binding sites, in-
cluding those for Sp1, GATA-1, AP1, AP2, CREB, estrogen 
and glucocorticoid receptors, NFB, STAT1, YY1, HIF-1 
and HSF-1, and PPAR [181] among others. It is likely that 
these sites influence transcriptional activity from the BACE1 
promoter.  
The brain is particularly susceptible to hypoxic condi-
tions and recent reports indicate that hypoxia can facilitate 
AD pathogenesis [173, 182]. During hypoxia, the hypoxia-
inducible factor-1 (HIF-1) transcription factor binds to the 
hypoxia-responsive element (HRE) in target gene promoters 
and activates genes involved in energy metabolism and cell 
death [183]. Importantly, an HRE has been recently identi-
fied in the BACE1 gene promoter at base pairs -915-911, 
and quantitative RT-PCR demonstrated that mouse BACE1 
mRNA expression, as observed for human BACE1 expres-
sion, appears to be upregulated by hypoxia at the level of 
gene transcription [173]. Indeed, the finding from in vitro 
assays indicating that hypoxia increased APP metabolism 
and A production via  BACE1 activity upregulation was 
confirmed in vivo [173].  
Transient hypoxic insult to cortical neurons can cause 
mitochondrial dysfunction. While A accumulation itself 
may lead to oxidative stress [144, 184], it has also been 
shown that oxidative stress may facilitate A accumulation. 
4hydroxy-2-nonenal (HNE), a marker of oxidative stress, has 
been identified at the early pathological stages of AD [160, 
161]. Interestingly, oxidative stress in vitro resulted in sig-
nificant increases in BACE1 promoter activity [171], and an 
increase in both BACE1 mRNA and protein levels, with in-
creased BACE1 activity being observed following HNE ex-
posure has been reported [169, 170]. 
Recent reports have documented BACE1 as a stress-
induced protease [169, 170, 172, 174, 185-187], and in view 
of the apparent importance of metabolic dysfunction and 
amyloidosis in AD, it is worth noting that BACE1 upregula-
tion has been observed under a variety of conditions includ-
ing hypoxia, energy disruption and/or mitochondrial stress 
(discussed below). Further support for the role of BACE1 in 
response to stress comes from observations of BACE1 eleva-
tion following traumatic brain injury (TBI), following which, 
increased levels of BACE1 mRNA in hippocampal and cor-
tical neurons were detected [186]. This increase was accom-
panied by a corresponding increase in BACE1 protein and 
activity.  
Neurons are responsible for the major portion of BACE1 
and A expression in the brain under normal conditions, and 
this is also likely to be true during AD. However, evidence is 
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significant levels of BACE1 and A, especially during in-
flammation. Indeed, a strong inflammatory reaction is pre-
sent in AD brain and long-term use of nonsteroidal anti-
inflammatory (NSAID) drugs reduces AD risk, suggesting 
inflammation may play an important role in AD pathophysi-
ology [188].  
Glia out-number neurons by ~10:1, so even a slight in-
crease in glial BACE1 expression might contribute substan-
tially to cerebral A and exacerbate AD pathology. NFB is 
increased in both aged and AD brain. Interestingly, Bourne 
[189] reported that NFB acts as a repressor in neurons but 
as an activator of BACE1 transcription in activated astro-
cytes present in the CNS during chronic stress, a feature ob-
served in AD. Furthermore, a functional NFB site in the 
BACE1 promoter was stimulated in A-exposed neural cells 
suggesting that elevated NFB in the brain may significantly 
contribute to increased A levels, acting as a positive feed-
back loop of chronic inflammation, astrocyte activation, and 
increased BACE1 transcription. Proinflammatory cytokines 
such as interferon  (IFN), tumor necrosis factor  (TNF) 
and interleukin  (IL1) have been shown to increase A 
secretion in cultured human astrocytes and astrocytic cell 
lines [190], and BACE1 levels rise, at least with IFN treat-
ment [191, 192]. Injection of INF into mouse brain led to 
elevated astrocytic BACE1 expression. Molecular analysis 
indicated that INF activated JAK2 and ERK1/2. Following 
phosphorylation, STAT-1 then binds to the putative STAT1 
binding sequence in the BACE1 promoter region to modu-
late astrocytic BACE1 expression [192]. In some studies, 
reactive astrocytes around amyloid plaques appear to display 
BACE1 immunoreactivity in both Tg2576 Tg mice that de-
velop amyloid pathology [193] and human AD brain [194-
196]. However, subsequent analyses by our group on other 
APP Tg and AD brains show that plaques elevate BACE1 in 
neurons not astrocytes [143]. This discrepancy probably re-
sults from the use of BACE1 antibodies in the earlier reports 
that were not monospecific for BACE1, while our study used 
a novel, extensively validated BACE1 antibody that does not 
cross-react with other proteins. Although the BACE1 eleva-
tion in AD primarily occurs in neurons, the amplified num-
ber of astrocytes in AD brain is likely to result in a signifi-
cant increase of astrocytic A production. 
Activation of PPAR with NSAIDs (e.g. ibuprofen) or 
PPAR agonists (e.g. pioglitazone) causes repression of 
BACE1 gene promoter activity, while proinflammatory cy-
tokines that reduce PPAR levels lead to increased BACE1 
mRNA [181]. Thus, the effects of inflammation and NSAIDs 
on AD may involve, at least in part, the action of PPAR on 
BACE1 gene expression. Interestingly, ibuprofen (and pio-
glitazone) treatment appeared to decrease BACE1 and re-
duce plaque load [197]. In the APP [V717I] Tg model of 
AD, BACE1 levels rose at focal sites of glial activation even 
before plaques begin to develop [198].  
Taken as a whole, the evidence suggests that astrocytes 
may express significant levels of BACE1 and contribute to 
A production, at least under certain proinflammatory condi-
tions. In addition to inflammation other conditions may 
cause BACE1 expression to increase in the brain, including 
oxidative stress, TBI, hypoxia and ischemia.  
THE POST-TRANSCRIPTIONAL REGULATION OF 
BACE1 
Paradoxically, in some studies BACE1 mRNA levels in 
either neurons or astrocytes around amyloid plaques in APP 
transgenic brain are not elevated [69, 143, 199], implying 
that a post-transcriptional mechanism may be responsible for 
the BACE1 increase. Increased BACE1 protein and/or activ-
ity in the absence of altered BACE1 mRNA levels might be 
caused by several factors including post-transcriptional proc-
essing, a change in the rate of BACE1 translation and/or 
alterations in BACE1 protein stability.  
The processing of pre-mRNA into multiple mRNA iso-
forms during alternative splicing is a powerful mechanism of 
genetic control. To date, four alternative splice variants of 
BACE1 have been identified and each encodes a protein 
isoform with different enzymatic activity [29, 30, 200-202]. 
Given the apparent elevation of BACE1 in AD brain, in the 
absence of BACE1 mRNA level elevation [134, 136], it is 
plausible that the differential expression of BACE1 isoforms 
may exert an effect on A formation. BACE1 variants arise 
as a consequence of the alternative splicing of exon 3 and/or 
exon 4, producing an in frame deletion of 75 (25 amino acid 
deletion; BACE-I-476), 132 (44 amino acid deletion; BACE-
I-457) and 207 (69 amino acid deletion; BACE-I-432) nu-
cleotides. Reports have indicated that, unlike the enzymati-
cally most active form BACE-I-501, both BACE-I-457 and 
BACE-I-476 lack -secretase activity and are retained in the 
ER [29, 30]. While most human brains regions express all 
four BACE1 variants, the frontal cortex expresses high lev-
els of BACE-I-501 and BACE-I-457 [200]. Interestingly, the 
same group examined the age-dependent differential expres-
sion of BACE1 and its four splice variants in six brain re-
gions of young (4 months) and old (ten months) Tg2576 
mice and compared them to wild-type litter mates [202]. The 
authors reported that BACE1 expression is regulated by age-
dependent post-transcriptional regulatory mechanism in 
Tg2576 mice. While total BACE1 mRNA levels did not 
change in Tg2576 mice, the expression profiles of the 
BACE1 splice variants not only differed between Tg and 
non-Tg mice, but also changed with age. While Tg2576 mice 
expressed more BACE-I-501 more significantly than the 
other splice variants, wild type mice demonstrated a more 
balanced variant expression. However, during aging, wild-
type mice undergo an increase in the relative abundance of 
the BACE1-I-501 variant. Young Tg2576 animals also ex-
pressed this BACE1 isoform at significantly higher levels as 
compared to age-matched wild-type mice. Given that 
Tg2576 mice overexpress human APP with the Swedish mu-
tation, Zohar and colleagues speculated that it was this APP 
overexpression in Tg2576 mice that effected the differential 
expression of BACE1 splice variants in these animals and 
suggested that APP may exert a regulatory role on BACE1 
transcripts. While these studies imply that splicing events are 
involved in the regulation of BACE1 enzymatic activity, the 
possible functions and brain distributions of BACE1 splice 
variants in AD brain remain to be established. As Zohar dis-
cusses, the differential expression of these variants may alter 
APP turnover and A production [202]. 
Features of BACE1 5’ untranslated region (5’UTR) such 
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the presence of upstream AUGs indicate that this 5’UTR 
may play an important role in the regulation of translational 
control and several studies indicate that BACE1 may be 
regulated in this fashion [203-205]. The use of BACE1 con-
structs devoid in part or all of the 5’UTR demonstrated that 
the presence of the 5’UTR could depress BACE1 translation 
significantly. Between the initiation site for transcription and 
the physiological translation initiation codon of the human 
BACE1 gene, there are 6 ATGs (uATGs) that could serve as 
translation initiation codons for five potential open reading 
frames (uORFs; [206]). The presence of such multiple up-
stream uORFs can inhibit the translation of the main ORF 
(reviewed in [207]). However, the mechanism by which the 
5’UTR regulates BACE1 gene expression remains elusive. 
While Rogers proposed a shunting mechanism in which the 
ribosomal unit scanning along the transcript leader can jump 
and bypass ribonucleotide stretches [204], others [203, 205] 
favored the so-called leaky-scanning and re-initiation 
mechanism in which inhibition was mainly dependent on 
secondary structures and upstream AUGs. This hypothesis 
was supported by recent data that demonstrated that during 
human BACE1 gene expression, ribosomes skipped some 
uAUGs by leaky scanning and translated an upstream ORF 
initiated at the fourth uAUG. BACE1 translation was subse-
quently re-initiated at the physiological AUG site. It was 
hypothesized that alterations in the leaky scanning and re-
initiation in BACE1 gene expression could be of importance 
in AD pathogenesis [206]. 
As previously indicated, increased BACE1 levels and ac-
tivity have been reported in both in vitro and in vivo under 
conditions of altered energy metabolism and cellular stress. 
It is practically impossible to differentiate energy inhibition 
from oxidative stress with regards to the pharmacological 
blockage of mitochondrial energetic processes in vivo as 
mitochondrial respiratory inhibitors are generally considered 
to cause oxidative stress [208]. In agreement with previous 
studies indicating that energy inhibition is potentially amy-
loidogenic [169-171], following acute energy inhibition in 
vivo we observed a significant elevation in BACE1 protein 
that appeared to correspond with a significant increase in 
cerebral A40 load in treated animals [172]. The mechanism 
of the energy-induced BACE1 increase in vivo is unclear and 
will likely be challenging to elucidate. While studies have 
demonstrated changes in BACE1 at the mRNA and protein 
levels following oxidative stress and hypoxic insults [170, 
173], our data indicates that translational control may be 
implicated in the in vivo BACE1 elevation during times of 
energy depletion [172]. BACE1 mRNA levels did not sig-
nificantly increase in Tg2576 brain following energy inhibi-
tion treatment and the BACE1 protein half life is too long to 
account for the rapid rise in BACE1 levels observed. As pre-
viously discussed reports indicate that the 5’UTR of BACE1 
mRNA influences translational efficiency. Furthermore, the 
stress-activated p38 pathway has been shown to control 
translation through the 5’UTR and is likely elevated during 
energy metabolic stress. Interestingly, the HNE-dependent 
upregulation of BACE1 expression observed in vitro, ap-
peared to be dependent on the activation of c-jun N-terminal 
kinases (JNK) and p38
MAPK [170]. Thus, we hypothesize that 
energy insufficiency, perhaps through p38, may elevate 
BACE1 mRNA translational efficiency via  the 5’UTR. 
Clearly, further, detailed analysis is required to solve this 
important issue, but full understanding of such cellular 
mechanisms may shed light on novel therapeutic approaches 
for AD. 
BACE1 ACTIVITY: POST-TRANSCRIPTIONAL AND 
POST-TRANSLATIONAL MODIFICATIONS 
The activity of the BACE1 enzyme is influenced by a 
number of factors, including splicing events, as previously 
discussed, the amount of BACE1 protein present (which is 
related directly to transcriptional and post-transcriptional 
events, along with altered BACE1 degradation), in addition 
to a variety of post-translational and cell biological events.  
The activation of specific intracellular signaling mole-
cules appears to be involved in the regulation of BACE1 
expression in the brain. Evidence is emerging for the modu-
lation of BACE1 expression by cholinergic receptor signal-
ing although the data is somewhat conflicting and the level at 
which BACE1 is modulated (transcriptional verses post-
transcriptional) remains unknown [209, 210]. Cholinergic 
dysfunction occurs early in the AD progression and many 
AD, FDA-approved therapeutics are aimed at improving 
cholinergic function [211]. While Zuchner reported that se-
lective stimulation of M1 muscarininc acetylcholine recep-
tors (mAChRs) increased BACE1 protein expression, with 
the activation of M2 mAChRs having opposing effects on 
the level of BACE1 protein [209], Caccamo and colleagues 
reported an impressive and almost complete inhibition of 
BACE1 protein expression following treatment of the 3xTg-
AD model with a selective M1 muscarinic agonist [210]. 
While the reasons for these opposing data remain unknown, 
the reversal of the effect by a M1 antagonist was not investi-
gated in the latter study, with the possibility that the ob-
served effect on BACE1 levels may be due to mechanisms 
other than M1 receptor activation. Future studies should clar-
ify this issue. 
The subcellular trafficking and localization of BACE1 
can impact the activity of this enzyme significantly. Hyper-
cholesterolemia is a metabolic derangement that contributes 
to cardiovascular diseases, and epidemiological [212, 213], 
animal [214, 215], and cellular studies [216, 217] suggest 
that alterations in cholesterol homeostasis contribute to AD 
etiology by enhancing A generation. During the exploration 
of the putative underlying molecular mechanisms of this 
apparent cholesterol-sensitive A generation, Ghribi and 
colleagues reported that, in comparison to controls, choles-
terol-fed rabbits exhibited elevated neuronal cholesterol lev-
els and this cholesterol appeared to co-localize with BACE1 
[218]. Furthermore, this association was accompanied by 
increases in both the level and activity of BACE1 and corre-
sponding elevations in A42. Such data indicate that the 
prevention of cholesterol accumulation, and/or cholesterol 
reduction may represent strategies for reduction of BACE1 
over activation. Indeed, mature BACE1 localizes largely 
within cholesterol-rich lipid rafts [95, 96]; this localization 
may be enhanced by palmitoylation, and various lipids sti- 
mulate BACE1 activity [219]. Replacing the BACE1 trans-
membrane domain with a glycosylphosphatidylinositol (GPI) 
anchor exclusively targets BACE1 to lipid rafts and substan-
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forming stable homodimers that exhibit enhanced catalytic 
activity [221, 222]. Of interest are data that indicate that a 
decrease in cellular cholesterol levels by the cholesterol low-
ering statin drugs, prevented BACE1 palmitoylation in vitro, 
which consequently prevented BACE1 dimerization, facili-
tated a change in the subcellular location of the enzyme and 
a subsequent reduction in A production [223, 224]. 
Interestingly, certain molecules have been shown to in-
hibit the BACE1-APP interaction and thus reduce -site 
cleavage, including heparan sulfate [225], reticulon/nogo 
proteins [112], and sorLA/LR11 [226]. These may provide 
clues for designing strategies to inhibit BACE1 therapeuti-
cally. Other molecules have been shown to interact with 
BACE1 and increase enzyme activity, like prostate apoptosis 
response-4 (PAR-4) protein [227], while the effects of other 
interacting partners, such as the copper chaperone for super-
oxide dismutase-1 [228] and the brain-specific Type II mem-
brane protein BRI3 [229], remain unclear. BACE1 and the -
secretase complex are essential for A genesis yet there is 
little data to support a functional relationship between 
BACE1 and the putative catalytic core of the -secretase 
complex. However, Kuzuya recently demonstrated that PS1 
may promote BACE1 maturation [230]. Indeed, a role for 
PS1 in protein trafficking has been previously demonstrated 
[231, 232]. Interestingly, data indicates that the correct dis-
tribution of BACE1 is crucial for A generation regulation, 
thus it is plausible that PS1 could somehow regulate BACE1 
trafficking, thereby modulating its maturation. 
Like APP, BACE1 cycles between compartments of the 
secretory pathway [233-235] and BACE1 activity resides in 
both the endosomes and secretory pathway. The intracellular 
trafficking and localization of the BACE1 protein is largely 
controlled by targeting signals present in the cytosolic por-
tion of the C-terminal tail [235]. The DISLL sequence in the 
C-terminus of the BACE1 cytosolic tail (amino acids 496-
500) is a so-called an acid cluster-dileucine motif (ACDL) 
and is known to be involved in endosomal trafficking. Dele-
tion of the ACDL motif [233] or mutation of the leucines to 
alanines [235] alters the subcellular distribution of BACE1, 
such that a greater proportion of the protein is localized at 
the cell surface and less is sequestered within endosomes.  
The ACDL of BACE1 binds to members of the Golgi-
localized  -ear containing ADP ribosylation factor-binding 
(GGA) family implicated in the sorting of cargo proteins 
between TGN and endosomes [236-240]. GGA1, 2 and 3 are 
monomeric adaptors involved in transport of proteins con-
taining the ACDL motif from the Golgi complex to the en-
dosome, from endosomes to the TGN in the recycling path-
way [239] and they may also be involved in the delivery of 
endosomal cargoes to the lysosome [241]. Koh and col-
leagues recently reported the lysosomal degradation of 
BACE1, and mutation of the di-leucine motif prevented 
lysosomal BACE1 accumulation following inhibition of 
lysosomal hydrolases [242]. Importantly, all three GGA pro-
teins appear to be involved in the trafficking of BACE as 
depletion of any of the three through RNAi caused a signifi-
cant BACE1 re-distribution [239]. GGA1 interacts with 
BACE1 and influences BACE1 trafficking through the recy-
cling pathway. The ACDL motif interaction with GGA1 is 
modulated by serine phosphorylation of the BACE1 motif 
[234, 235, 237-239]. BACE1 phosphorylation at the S498 
site and interaction with GGA proteins regulate the transport 
and recycling of the enzyme between early and late en-
dosomes and the TGN. Whether dephosphorylation regulates 
BACE1 trafficking in other parts of the trafficking cycle 
remains to be determined. Although BACE1 phosphoryla-
tion does not appear to dramatically alter -secretase activity 
in experimental systems, BACE1 trafficking may have a 
significant impact on A production in the brain.  
Overexpression of GGA1 led to an increase in the levels 
of both immature BACE1 and APP species [243]. Despite 
the immature status of BACE1, APP metabolism still oc-
curred and elevations in C99 and APPs were observed. 
However, levels of A were reduced, data indicative that 
GGA1 blocked APP -cleavage products from becoming -
secretase substrates. It was demonstrated that GGA1 con-
fined APP to the Golgi [243]. Thus not only does GGA1 
interact with BACE1, but it acts also as a sorting protein that 
affects APP trafficking and ultimately the proteolysis of this 
molecule [243, 244]. Interestingly, a very recent report has 
highlighted the individual roles of the GGA proteins in me-
diating BACE1 trafficking. In contrast to GGA1, Tesco and 
colleagues demonstrated that an inhibition of GGA3, via 
RNAi, led to an elevation of BACE, C99 and A [185].  
BACE1 can be degraded by at least three mechanisms: 1. 
endoproteolysis within its catalytic domain [245]; 2. the 
ubiquitin-proteasomal pathway [246]; 3. the lysosomal path- 
way [242]. Evidence for altered BACE1 degradation first 
came from Puglielli and colleagues who reported that the 
lipid second messenger, ceremide, increases BACE1 half-life 
and the generation of A [247]. Interestingly, the same group 
reported that treatment of neuroblastoma cells expressing the 
p75 neurotrophin receptor (p75
NTR) with nerve growth factor, 
elevates both ceremide and BACE1 levels [248]. The authors 
demonstrated a link with the aging process, the single most 
important risk factor for AD, whereby normal aging acti-
vates A generation in the brain by “switching” from the 
tyrosine kinase receptor A system to that mediated by 
p75
NTR. Indeed the Puglielli group have just reported that 
ceremide stimulates the carrier-mediated translocation of 
acety-CoA into the lumen of the ER, a prerequisite for the 
lysine acetylation of BACE1 (detailed previously) that is 
necessary for BACE1 maturation and stabilization [92].  
Occlusion of the middle cerebral artery is a widely ac-
cepted experimental stroke model used to study the effects of 
transient cerebral ischemia. Not only did ischemia lead to an 
elevation in BACE1 protein and activity but data from co-
localization experiments indicated that BACE1 immunoreac-
tivity was strongly associated with TUNEL staining, a 
marker of apoptosis [187]. Interestingly, a recent study has 
revealed a potential molecular mechanism that may underlie 
the BACE1 increase following ischemic episodes [185]. 
Whilst it is appears that ischemia induces apoptosis, the con-
tribution of apoptosis to AD pathogenesis remains unclear 
although there is increasing evidence for caspase activation 
in the AD brain (reviewed in [249, 250]). However, apopto-
sis enhances A levels in both neuronal and non-neuronal 
populations and in the recent study from Tesco and col-
leagues [185], BACE1 levels and associated activity were 
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ing programmed cell death induced the BACE1 increase via 
a post-translational stabilization of BACE1 and a significant 
impairment in BACE1 degradation and turnover. As previ-
ously detailed, the GGA adaptor proteins are implicated in 
the subcellular trafficking of BACE1. Tesco demonstrated 
that GGA3 is cleaved by activated caspase-3 during apopto-
sis. In the rat ischemia model, this reduction in GGA3 levels 
was co-ordinated with caspase activation and increased 
BACE1 protein levels. Furthermore, RNAi silencing of 
GGA3 caused an increase in the level and activity of BACE1 
as determined by elevations in C99 and A. Indeed, He et al. 
have previously demonstrated that RNAi-mediated depletion 
of GGAs significantly increases endosomal BACE1 levels 
[239]. Degradation of BACE1 occurs, in part at least, in the 
lysosomal pathway [242] and a role for GGA3 in the target-
ing of cargo to the lysosome has been previously reported 
[241]. Thus, Tesco and colleagues suggested that apoptosis, 
caused by ischemic events, drives GGA3 depletion and re-
sults in the stabilization and accumulation of BACE1 leading 
to elevated enzymatic activity. Importantly, in AD brain, 
GGA3 protein levels were significantly decreased and in 
AD-relevant regions, this decrease was inversely correlated 
with elevations in BACE1 [185]. While other post-transla- 
tional mechanisms may account for this observed decrease in 
GGA3, it is tempting to speculate that apoptotic events may 
play a role in the increase in BACE1 in AD brain, indeed, 
elevated BACE1 activity may lead to increased A levels 
and, given that A can induce apoptosis, this could poten-
tially trigger a vicious cycle that self-potentiates A genera-
tion and cell death. 
CONCLUDING REMARKS 
Almost a decade since the initial identification of BACE1 
as the -secretase our understanding of this enzyme contin-
ues to increase. BACE1 is a clear drug target for inhibiting 
A production, and it is highly likely that a partial inhibition 
of BACE1 activity may be beneficial, although the percent-
age of BACE1 inhibition required to significantly delay 
amyloid pathology and the associated cognitive changes re-
quires further determination. 
While the physiological role (s) of BACE1 remain to be 
conclusively determined, indications are that BACE1 may 
function as a stress response protein. Not only are several 
recently identified BACE1 substrates involved in the re-
sponse to stress and/or injury such as axonal growth and the 
regulation of glial cell survival (NRG1; [251]), recovery from 
excitotoxicity (A; [106]), A clearance (LRP; [252]), syn-
apse formation (APP, APLP1, APLP2; [253, 254]), neuro-
protection (secreted APP ectodomain; reviewed in [255]) 
and immune functions (PSGL-1, ST6Gal I and IL-1R2; [128, 
129, 132]), but BACE1 levels are elevated during stressful 
conditions, including those related to vascular disease [134, 
141, 143, 169-174, 218]. We suggest that the elevation in 
BACE1 levels facilitates the recovery after acute stress/ 
injury and it is plausible that cleavage of BACE1 substrates 
is necessary for this function.  
However, it remains a possibility that chronic stress/ 
injury results in pathologic BACE1 levels and deleterious 
amyloid formation. Indeed, the elevation in BACE1 ob-
served in AD may provide a molecular link between known 
AD risk factors (such as vascular disease and injury) and AD 
pathogenesis, and the molecular mechanisms governing 
these associations are being intensely investigated. Interest-
ingly, vascular disease and its downstream consequences, 
together with TBI, have been linked to alterations in BACE1 
on a variety of levels, both transcriptional and post-
transcriptional. Where as TBI, hypoxia, oxidative stress, and 
inflammation may affect levels of BACE1 mRNA [169-171, 
173, 181, 182], energy deficiency and metabolic stress might 
impact the translation of BACE1 [172]. BACE1 activity is 
also affected by the microenvironment, being stimulated by 
various lipid moieties [219], and the stability of BACE1 may 
be affected by ischemic conditions [185]. Clearly further 
understanding of the molecular mechanisms of BACE1 ele-
vation during AD may accelerate the development of novel 
therapeutic strategies to treat this neurodegenerative disease. 
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ABBREVIATIONS 
AD =  Alzheimer’s  disease 
A =  -amyloid 
APP  =  Amyloid precursor protein 
BACE1 =  -site APP Cleaving Enzyme 1 
FAD =  Familial  AD 
PS =  Presenilin 
DS =  Down’s  syndrome 
LOAD  =  Late onset AD 
ApoE =  Apolipoprotein  E 
CTF =  Carboxyl  terminal  fragment 
AICD  =  APP intracellular domain 
TACE =  TNF- converting enzyme 
ADAM  =  A disintegrin and metalloprotease domain  
protein 
TGN  =  Trans Golgi network 
BACE1
-/- =  BACE1  knockout 
Tg =  Transgenic 
SNP  =  Single nucleotide polymorphism 
ER =  Endoplasmic  reticulum 
PC =  Proprotein  convertase 
CSF  =  Cerebral spinal fluid 
APLP =   Amyloid precursor-like proteins The Basic Biology of BACE1  Current Genomics, 2007, Vol. 8, No. 8    523 
NRG1 =  Neuregulin  1 
PNS  =  Peripheral nervous system 
CNS =  Central  nervous  system 
VGSC  =  Voltage-gated sodium channel 
RIP =  Regulated  intramembrane  proteolysis 
LRP  =  Lipoprotein receptor-related protein 
ICD =  Intracellular  domain 
PSGL-1  =  P-selectin glycoprotein ligand 1 
ST6Gal1 =  Beta-galactoside  alpha  2,6-sialyltransferase 
IL-1R2  =  Interleukin-1 receptor II 
CBF  =  Cerebral blood flow 
CBH  =  Chronic brain hypoperfusion 
MCI =  Mild  cognitive  impairment 
HIF-1  =  Hypoxia-inducible factor 1 
HRE =  Hypoxia-responsive  element 
HNE =  4hydroxy-2-nonenal 
TBI  =  Traumatic brain injury 
NSAIDS  =  Nonsteroidal anti-inflammatory drugs 
PPAR  =  Transcriptional regulator proliferator-activated 
receptor  
INF =  Interferon   
F  =  Tumor necrosis factor  
IL1 =  Interleukin   
UTR =  Untranslated region 
uORFs  =  Open reading frames 
mAChR  =  Muscarinic acetylcholine receptor 
GPI =  Glycosylphosphatidylinositol 
PAR-4  =  Prostate apoptosis response-4 
ACDL  =  Acid cluster-dileucine motif 
GGA =  Golgi-localized  -ear containing ADP  
ribosylation factor-binding 
RNAi =  RNA  interference 
EGF  =  Epidermal growth factor 
PI3K =  Phospatidylinositol-3-OH  kinase 
JNK  =  c-jun N-terminal kinases 
P75
NTR  =  p75 neurotrophin receptor 
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